HemoSphere Alta™ Advanced Monitoring Platform with Predictive, Smart Algorithms Helps Clinicians Proactively Address Instability in Blood Flow and Pressure in Critical SituationsFRANKLIN LAKES, N.J., April 21, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, has launched a new advanced hemodynamic monitoring platform with predictive, artificial intelligence (AI) based algorithms that can help clinicians proactively address blood pressure insta ...

Group 1 - The article emphasizes the importance of long-term investing over market timing, highlighting that successful investing requires patience and a focus on consistent growth rather than short-term fluctuations [1] - The author shares personal experiences in managing an IRA and building a portfolio, aiming to inspire other DIY investors, particularly those on a limited budget [2] - The investment strategy primarily focuses on dividend-paying stocks with a history of consistent earnings and dividend growth, aligning with goals for retirement savings and funding education [2] Group 2 - The author holds long positions in a diverse range of companies, including AAPL, MSFT, and XOM, indicating a broad investment strategy across various sectors [3] - The article does not serve as professional investment advice, and readers are encouraged to conduct their own due diligence before making investment decisions [4][5]

Becton, Dickinson and Company (BDX) , popularly known as BD, is evaluating the divestment of its Life Sciences division as part of a broader strategic shift toward becoming a pure-play medtech company. According to a Financial Times report, BD has initiated discussions with several potential buyers, including Thermo Fisher Scientific, Danaher and a group of smaller diagnostics companies. This move follows BD’s February announcement that it would explore strategic alternatives for the unit, including a full ...

FRANKLIN LAKES, N.J., April 3, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD management will host an audio webcast at 8 a.m. ET on Thursday, May 1, 2025 to discuss the Company's financial results for its second quarter of fiscal year 2025, which ended on March 31, 2025, and to provide an update on its operations and strategy. The audio webcast can be accessed at BD's investor relations website at www.bd.com/investors ...

FRANKLIN LAKES, N.J., March 31, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today was named to Fortune's 2025 list of America's Most Innovative Companies, ranking in the top 25% of companies overall. The list recognizes organizations that excel in developing innovative products, streamlining processes, and cultivating a forward-thinking corporate culture. "As one of the largest manufacturers of medical devices in the world whose products ...

FRANKLIN LAKES, N.J., March 27, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of Gregory J. Hayes to its board of directors, effective March 26, 2025. BD appoints Gregory J. Hayes to its board of directors. Hayes, 64, is currently the executive chairman of the board of directors of RTX Corporation, the world's largest aerospace and defense company. He brings more than 30 years of extensive executive expe ...

Becton, Dickinson and Company’s (BDX) , or popularly known as BD, initiated the recall of its infusion pumps last month after customer reports indicated software issues, potentially leading to inaccurate therapy administration. The FDA designated BD’s recall of its infusion pump software as Class I, the most severe classification, last week. While no injuries or fatalities have been reported, the FDA warns that continued use of the affected software could result in serious harm or even death if appropriate ...

Becton, Dickinson and Company (BDX) , popularly known as BD, recently announced the first patient treated under an Investigational Device Exemption, aiming to secure FDA Premarket Approval for its GalaFLEX LITE Scaffold. The trial focuses on evaluating the scaffold's ability to reduce the recurrence of capsular contracture (“CC”) in breast revision surgeries.By advancing this innovative solution, BD is working to address unmet needs in breast reconstruction procedures. The trial reflects the company’s commi ...

FRANKLIN LAKES, N.J., March 20, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the first patient treated in an Investigational Device Exemption (IDE) clinical trial intended to advance BD's efforts to achieve Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA) for the use of GalaFLEX LITE™ Scaffold in decreasing capsular contracture (CC) recurrence during breast revision surgery. BD's Bioabsorbable Ga ...

Core Insights - The Zacks Premium service provides tools for investors to enhance their stock market engagement and confidence, including daily updates, research reports, and stock screens [1] Zacks Style Scores - Zacks Style Scores are indicators that assist investors in selecting stocks likely to outperform the market within 30 days, rated from A to F based on value, growth, and momentum characteristics [2] - The Value Score focuses on identifying undervalued stocks using financial ratios like P/E and Price/Sales to find attractive investment opportunities [3] - The Growth Score emphasizes a company's financial health and future outlook, analyzing projected and historical earnings and cash flow to identify sustainable growth stocks [4] - The Momentum Score helps investors capitalize on price trends by evaluating recent price changes and earnings estimate shifts to identify high-momentum stocks [5] - The VGM Score combines all three Style Scores, providing a comprehensive indicator for investors who utilize multiple investment strategies [6] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to simplify portfolio building, with 1 (Strong Buy) stocks achieving an average annual return of +25.41% since 1988, significantly outperforming the S&P 500 [7][8] - Investors are encouraged to select stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B to maximize potential returns [10] - The direction of earnings estimate revisions is crucial; stocks with lower ranks but high Style Scores may still face downward price pressure [11] Company Spotlight: Becton Dickinson (BDX) - Becton Dickinson, a medical technology company, is currently rated 3 (Hold) with a VGM Score of B, and has shown a 1.4% increase in share price over the past four weeks [12] - Recent upward revisions in earnings estimates by five analysts for fiscal 2025 have raised the Zacks Consensus Estimate to $14.43 per share, with an average earnings surprise of 7.3% [13]